Rachel Leheny
Chief Executive Officer at CALCIMEDICA, INC.
Net worth: 586 799 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Eric Roberts | M | 59 |
Valence Life Sciences LLC
 Valence Life Sciences LLC Investment ManagersFinance Valence Life Sciences LLC (Valence Life Sciences) is an venture capital firm founded in 2012 by Rachel Anne Leheny and Eric Wayne Roberts. The firm is headquartered in New York.
Valence Investments SPV IV LLC
 Valence Investments SPV IV LLC BiotechnologyHealth Technology Valence Investments SPV IV LLC engages in the provision of biotechnology services. The company is headquartered in New York, NY.
CalciMedica, Inc. (US)
 CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA.
Lehman Brothers, Inc.
 Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | 14 years |
| Michael Dunn | M | 68 |
CalciMedica, Inc. (US)
CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA. | 11 years |
| Kenneth Stauderman | M | 71 |
CalciMedica, Inc. (US)
CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA. | 18 years |
| Fred Middleton | M | 74 |
CalciMedica, Inc. (US)
CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA. | 4 years |
| Allan Shaw | M | 59 |
CalciMedica, Inc. (US)
CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA. | 3 years |
| Robert McNeil | M | 81 |
DalCor Pharmaceuticals Canada, Inc.
 DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | - |
| Robert Wilson | M | 83 |
CalciMedica, Inc. (US)
CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA. | 4 years |
| Royston Glasspool | M | 61 |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | 7 years |
| Daniel Geffken | M | 67 |
CalciMedica, Inc. (US)
CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA. | 4 years |
| Sudarshan Hebbar | M | 59 | 9 years | |
| Eric Bjerkholt | M | 64 | 1 years | |
| Graham K. Crooke | M | 65 |
Valence Investments SPV IV LLC
Valence Investments SPV IV LLC BiotechnologyHealth Technology Valence Investments SPV IV LLC engages in the provision of biotechnology services. The company is headquartered in New York, NY. | - |
| Fouzia Laghrissi-Thodes | M | 61 |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | 6 years |
| Raven Jaeger | F | 46 | 1 years | |
| Frédéric Guerard | M | 51 | 1 years | |
| Domitille de Vienne | F | - |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | - |
| Henry d'Abo | M | - |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | - |
| Zafrira Avnur | M | 73 |
CalciMedica, Inc. (US)
CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA. | 3 years |
| Richard Friesner | M | 71 |
The Trustees of Columbia University in The City of New York
| 34 years |
| Paul Glasserman | M | 62 |
The Trustees of Columbia University in The City of New York
| 33 years |
| Laurence Rulleau | M | - |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | - |
| Mark L. Smith | M | - |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | - |
| Paul J. Maddon | M | 64 |
The Trustees of Columbia University in The City of New York
| 35 years |
| Rody Yared | M | - |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | - |
| Paul R. Fonteyne | M | 62 |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | 5 years |
| Serge Langford | M | - |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | - |
| John Dunn | M | 72 | 1 years | |
| Andrew Cunningham | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Deepak Mohan Narula | M | - |
Lehman Brothers, Inc.
Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues.
The Trustees of Columbia University in The City of New York
| 14 years |
| Len Berman | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Duke S. Shin | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Dan Niles | M | - |
Lehman Brothers, Inc.
Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | 3 years |
| J. Ari Tuchman | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Kyle Loudermilk | M | - |
The Trustees of Columbia University in The City of New York
| 5 years |
| Jeffrey Allen Ferrell | M | 49 |
Lehman Brothers, Inc.
Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | 7 years |
| Scott Morenstein | M | 48 |
Valence Life Sciences LLC
Valence Life Sciences LLC Investment ManagersFinance Valence Life Sciences LLC (Valence Life Sciences) is an venture capital firm founded in 2012 by Rachel Anne Leheny and Eric Wayne Roberts. The firm is headquartered in New York.
Caxton Advantage Venture Partners
 Caxton Advantage Venture Partners Investment ManagersFinance Founded in 2004 by Eric Roberts and Rachel Leheny, Caxton Advantage Venture Partners is a venture capital firm located in New York City. | 1 years |
| Harry Mateer | M | - |
Lehman Brothers, Inc.
Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | 8 years |
| Jay Cecil | M | - |
Valence Life Sciences LLC
Valence Life Sciences LLC Investment ManagersFinance Valence Life Sciences LLC (Valence Life Sciences) is an venture capital firm founded in 2012 by Rachel Anne Leheny and Eric Wayne Roberts. The firm is headquartered in New York.
Caxton Advantage Venture Partners
Caxton Advantage Venture Partners Investment ManagersFinance Founded in 2004 by Eric Roberts and Rachel Leheny, Caxton Advantage Venture Partners is a venture capital firm located in New York City. | 6 years |
| Joon-Ho Hahm | M | - |
The Trustees of Columbia University in The City of New York
| 6 years |
| Ronald A. Fleming | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Gaurav Tejwani | M | - |
Lehman Brothers, Inc.
Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | 7 years |
| Jay Radtke | M | - |
Lehman Brothers, Inc.
Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | 3 years |
| Simon White | M | 65 |
Lehman Brothers, Inc.
Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | 7 years |
| Peter Thompson | M | 64 | 2 years | |
| Alex Barros | M | - |
The Trustees of Columbia University in The City of New York
| 5 years |
| Lakhmir Chawla | M | 53 |
CalciMedica, Inc. (US)
CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA. | 5 years |
| Scott P. Hall | M | 56 |
The Trustees of Columbia University in The City of New York
| 6 years |
| William Garrahan | M | 66 |
Lehman Brothers, Inc.
Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | 5 years |
| Steven Gutterman | M | 55 |
The Trustees of Columbia University in The City of New York
| 5 years |
| Petru Ion Vãduva | M | 64 |
The Trustees of Columbia University in The City of New York
| 7 years |
| Dan Spiegelman | M | 65 | 4 years | |
| Kartik Seshan | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Sanjeiiv Geeta Chaudhry | M | 63 |
The Trustees of Columbia University in The City of New York
| 3 years |
| Kevin Wong | M | 55 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Richard Weil | M | 55 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Li Xin Xu | M | 57 |
The Trustees of Columbia University in The City of New York
| 5 years |
| EunJung Cardiff | F | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Massimo Acquaviva | M | 57 |
The Trustees of Columbia University in The City of New York
| - |
| Tracy Lee Maeter | F | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Umberto Mosetti | M | 59 |
The Trustees of Columbia University in The City of New York
| 3 years |
| Seong-Soo Go | M | 60 |
The Trustees of Columbia University in The City of New York
| 1 years |
| Rich Cheung | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Michael Thomas Girouard | M | 58 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Doug Scott | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Stephen Rand Stonberg | M | 56 |
The Trustees of Columbia University in The City of New York
| 4 years |
| David Richard Nelson | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Amer Bisat | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Dena Bravata | M | 57 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Chris K. Lavagnino | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Gilbert Greenman | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Chris E. Beach | M | 54 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Laura A. Smoliar | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Albert Rabil | M | 61 |
The Trustees of Columbia University in The City of New York
| 2 years |
| Andrew Carey Callaghan | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Helene L. Kaplan | F | 90 |
The Trustees of Columbia University in The City of New York
| 3 years |
| Charles Homcy | M | 75 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Michael V. Oporto | M | - |
The Trustees of Columbia University in The City of New York
| 1 years |
| Mike Odrich | M | 60 |
The Trustees of Columbia University in The City of New York
| 1 years |
| David Chan | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Vincent C. DuPont | M | - |
The Trustees of Columbia University in The City of New York
| 6 years |
| Brian Murphy | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Yumi Koh | F | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Keith Lee | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Jeff Klein | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Matt Ripperger | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Diego J. Orlanski | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Byung Joon Han | M | 64 |
The Trustees of Columbia University in The City of New York
| 3 years |
| Wai Hung Ma | M | 59 |
The Trustees of Columbia University in The City of New York
| 2 years |
| Jake Rothenberg | M | - |
Hambrecht & Quist Group, Inc.
 Hambrecht & Quist Group, Inc. Investment Banks/BrokersFinance Hambrecht & Quist Group, Inc. operates as a holding investment bank and provides securities brokerage services. The company is headquartered in San Francisco, CA. | 1 years |
| Chris Tessin | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Toyoki Sameshima | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Bryan Paul | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Ge Li | M | 56 |
The Trustees of Columbia University in The City of New York
| 3 years |
| Jon G. Finkelstein | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Robert Kramer | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Elijah Duckworth-Schachter | M | 55 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Michael S. Fruchtman | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Andrew Paul Hofer | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| David Niles Lubell | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Sin-Kyu Park | M | 61 |
The Trustees of Columbia University in The City of New York
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 90 | 90.00% |
| Canada | 10 | 10.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Rachel Leheny
- Personal Network
